所有图片(1)
About This Item
经验公式（希尔记法）:
C15H14N4O
CAS号:
分子量:
266.30
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推荐产品
化驗
≥98% (HPLC)
形狀
powder
顏色
white to tan
溶解度
DMSO: ≥22 mg/mL
儲存溫度
room temp
SMILES 字串
CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O
InChI
1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
InChI 密鑰
NQDJXKOVJZTUJA-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
應用
Nevirapine has been used as non-nucleoside reverse transcriptase inhibitor in in vitro porcine endogenous retrovirus replication, primary hepatocytes and bone marrow dendritic cells (BMDCs).
生化／生理作用
奈韦拉平是 HIV 逆转录酶（NNRTI）的变构非核苷抑制剂。奈韦拉平抑制野生型 RT 的 Ki 为 200 nM。
Nevirapine interacts with glycine 190 residue of human immuno deficiency virus (HIV-2) reverse transcriptase. It is an antiretroviral drug which increases bile synthesis and activates electron transport chain. Use of nevirapine leads to liver toxicity and is associated with Nevirapine hypersensitivity syndrome.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes
Terelius Y, et al.
Chemico-Biological Interactions, 255, 31-44 (2016)
The N-terminal domain of cGAS determines preferential association with centromeric DNA and innate immune activation in the nucleus
Gentili M, et al.
Testing, 26(9), 2377-2393 (2019)
Etienne Audureau et al.
BMC public health, 13, 286-286 (2013-04-04)
Uptake of prevention of mother-to-child HIV transmission (PMTCT) programs remains challenging in sub-Saharan Africa because of multiple barriers operating at the individual or health facility levels. Less is known regarding the influence of program-level and contextual determinants. In this study
Complications of long-term antiretroviral therapy in HIV-infected children.
Andrew J Prendergast
Archives of disease in childhood, 98(4), 245-246 (2013-02-16)
Douglas Ward et al.
Journal of the International Association of Providers of AIDS Care, 12(3), 154-156 (2013-03-02)
Nevirapine (NVP) was the first nonnucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV infection. NVP can provide safe and efficacious viral suppression for treatment-naive patients and for virologically controlled patients "switching" from other NNRTI or protease inhibitor-based
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门